EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China

Siming Li, Yanxia Shi, Haiying Dong, Hongqian Guo, Yu Xie, Zhongquan Sun, Xiaoping Zhang, Eric Kim, Jun Zhang, Yue Li, Chenming Xu, Haishan Kadeerbai und 4 weitere

Cancer Medicine · 2024-11 · 13 (21)

DOI: 10.1002/cam4.70368 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, online erschienen am 12.11.2024. Verfasst von Siming Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seagen Inc., a wholly owned subsidiary of Pfizer, Astellas Pharma, Inc., Seagen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Enfortumab vedotin, a fully human monoclonal antibody–drug conjugate (ADC) directed to Nectin‐4, prolonged overall survival (OS) versus standard chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma (mUC) previously receiving a programmed cell death protein 1/ligand 1 (PD‐1/L1) inhibitor and platinum‐based chemotherapy in the pivotal, phase 3 EV‐301 clinical trial, supporting global approvals of enfortumab vedotin monotherapy. This bridging study was the first to evaluate enfortumab vedotin monotherapy in previously treated Chinese patients with locally advanced or mUC.

Methods

EV‐203 was a multicenter, open‐label, phase 2 study (NCT04995419) assessing efficacy, safety/tolerability, pharmacokinetics (PK), and immunogenicity of enfortumab vedotin in 40 Chinese patients (PK analysis set, n = 13) with previously treated locally advanced or mUC. Patients received enfortumab vedotin 1.25 mg/kg (Days 1, 8, and 15). Primary endpoints included confirmed objective response rate (ORR) by the independent review committee (IRC) and PK parameters of ADC, total antibody (TAb), and free monomethyl auristatin E (MMAE). Secondary endpoints included investigator‐assessed confirmed ORR; investigator‐/IRC‐assessed duration of response (DOR), disease control rate (DCR), and progression‐free survival (PFS); OS; immunogenicity; and safety/tolerability.

Results

As of May 13, 2022, the median follow‐up was 6.5 months. Confirmed ORR was 37.5% (n/ N = 15/40; 95% CI: 22.7%–54.2%) by IRC and 42.5% (n/ N = 17/40; 95% CI: 27.0%–59.1%) by investigator assessment. By IRC, DCR was 72.5% ( n = 29), median DOR was not reached, and median PFS was 4.7 months. Median OS was not reached. Endpoints assessed by investigators were consistent with IRC assessments. Two patients discontinued treatment for treatment‐related adverse events. No new safety signals were identified. ADC, TAb, and free MMAE were characterized in Chinese patients and consistent with previously characterized populations. The incidence of positive antitherapeutic antibodies postbaseline was 0%.

Conclusion

Enfortumab vedotin demonstrated meaningful clinical activity with a manageable safety profile in Chinese patients with previously treated locally advanced or mUC. Trial Registration ClinicalTrials.gov identifier: NCT04995419

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalHumansMaleFemaleMiddle AgedAgedChinaImmunoconjugatesAdultAged, 80 and overCarcinoma, Transitional CellAntineoplastic Agents, ImmunologicalUrologic NeoplasmsUrinary Bladder Neoplasms

Stichwörter der Autor:innen

antibody–drug conjugatesefficacymonomethyl auristatin Esafetyurothelial carcinoma

Substanzen

enfortumab vedotinAntibodies, MonoclonalImmunoconjugatesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou, China.
  • Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, China.
  • Department of Urology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan, China.
  • Department of Urology, Huadong Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Jun Guo

Förderung

  • Seagen Inc., a wholly owned subsidiary of Pfizer
  • Astellas Pharma, Inc.
  • Seagen
  • Astellas Pharma

Zitieren

APA

Li, S., Shi, Y., Dong, H., Guo, H., Xie, Y., Sun, Z., Zhang, X., Kim, E., Zhang, J., Li, Y., Xu, C., Kadeerbai, H., Lee, S., Gorla, S., Guo, J., & Sheng, X. (2024). Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China. Cancer Medicine, 13(21). https://doi.org/10.1002/cam4.70368

Vancouver

Li S, Shi Y, Dong H, Guo H, Xie Y, Sun Z, et al. Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China. Cancer Medicine. 2024;13(21). doi:10.1002/cam4.70368

BibTeX
@article{Li2024,
  author = {Li, Siming and Shi, Yanxia and Dong, Haiying and Guo, Hongqian and Xie, Yu and Sun, Zhongquan and Zhang, Xiaoping and Kim, Eric and Zhang, Jun and Li, Yue and Xu, Chenming and Kadeerbai, Haishan and Lee, Sue and Gorla, Seema and Guo, Jun and Sheng, Xinan},
  title = {Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {21},
  doi = {10.1002/cam4.70368}
}
Kostenlos starten →